CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Newest patents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Close

Silica-based nanoparticles targeting cancer cell for photodynamic therapy

Reference

02212-01

Patents status

Priority patent application FR0805034 filed on September 15, 2008 entitled “Dérivés de métalloporphyrines, nanoparticules les comprenant”

Inventors

David BREVET
Ouhiba HOCINE
Jean-Olivier DURAND
Philippe MAILLARD
Alain MORERE
Marcel GARCIA
Monique SMAIHI
Magali GARY-BOBO

commercial status

Exclusive or non-exclusive licenses

Laboratory

Institut Charles Gerhardt, Institut de Chimie Moléculaire et des Matériaux de Montpellier (UMR 5253), Montpellier, France, http://www.icgm.fr

Description

CONTEXT

Photodynamic therapy (PDT) is an emerging modality for the treatment of a variety of oncological, cardiovascular, dermatological and ophthalmic diseases. In PDT, irradiated photosentisizers that surround or enter cells transfer their energy to molecular oxygen, thus forming highly reactive singlet oxygen (1O2) and other reactive oxygen species which, in turn, kill the nearby cells. This invention related to nanovectors which jointly ensure cancer cells targeting and two-photon imaging as well as their mono or biphotonic photodynamic therapy (PDT).

TECHNICAL DESCRIPTION

The vectors are silica-based nanoparticles that encapsulate fluorescent photosensitizers. The confinement of a photosensitizer in a solid matrix allow its use in biological environments. The photosensitizers are enable, by mean of biphotonic excitation, a high resolution cancer cells imaging. A singlet oxygen production inside the cells are assured by mono or biphotonic excitation.

BENEFITS

Nanoparticules are biocompatible, biodegradable, and highly specific. With this technology, PDT side effects are reduced thanks to a cell targeting. Moreover, irradiations at near infrared light confer a better tissue penetration leading to improved treatment efficiency. PDT also offers a lot of advantages such as minimally invasive and minimally toxic therapy. Furthermore, PDT is non mutagenic compared to radio or chemotherapy which is an advantage for cancers such as retinoblastoma. Comparing current treatment of cancers, PDT is much cheaper alternative. Moreover, for patient, PDT post-operative recovery is better requiring hours or days rather than weeks.

INDUSTRIAL APPLICATIONS

Treatment of a wide variety of solid cancers, including deep tissue and multisite cancers.
Treatment of a variety of dermatologic conditions, including actinic keratoses, photoaging and other cutaneous concerns.

DEVELOPMENT STAGE

The PDT treatments are under study in vivo with mice bearing xenografted tumors. Preliminary experiments with two-photon PDT on mice with colon cancer showed a reduction of 70% of the tumor mass.

For further information, please contact us (Ref 02212-01)

 


Need further information ?

Contact us
Close

Contact us

  • This field is for validation purposes and should be left unchanged.
Close

Newest patents